Mineralys Therapeutics Inc (NASDAQ: MLYS) kicked off on Monday, down -4.15% from the previous trading day, before settling in for the closing price of $16.87. Over the past 52 weeks, MLYS has traded in a range of $8.24-$18.38.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -6.33%. With a float of $36.97 million, this company’s outstanding shares have now reached $49.82 million.
The firm has a total of 51 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Mineralys Therapeutics Inc (MLYS) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Mineralys Therapeutics Inc is 41.12%, while institutional ownership is 46.20%. The most recent insider transaction that took place on Mar 13 ’25, was worth 8,100,000. In this transaction 10% Owner of this company bought 600,000 shares at a rate of $13.50, taking the stock ownership to the 5,674,916 shares. Before that another transaction happened on Mar 13 ’25, when Company’s Director bought 600,000 for $13.50, making the entire transaction worth $8,100,000. This insider now owns 5,674,916 shares in total.
Mineralys Therapeutics Inc (MLYS) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -6.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -3.06% during the next five years compared to -170.42% drop over the previous five years of trading.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Trading Performance Indicators
Take a look at Mineralys Therapeutics Inc’s (MLYS) current performance indicators. Last quarter, stock had a quick ratio of 14.02.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -3.96 in one year’s time.
Technical Analysis of Mineralys Therapeutics Inc (MLYS)
Analysing the last 5-days average volume posted by the [Mineralys Therapeutics Inc, MLYS], we can find that recorded value of 1.36 million was better than the volume posted last year of 0.86 million. As of the previous 9 days, the stock’s Stochastic %D was 69.30%. Additionally, its Average True Range was 1.34.
During the past 100 days, Mineralys Therapeutics Inc’s (MLYS) raw stochastic average was set at 78.20%, which indicates a significant increase from 74.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 156.23% in the past 14 days, which was higher than the 95.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.99, while its 200-day Moving Average is $12.17. Now, the first resistance to watch is $16.96. This is followed by the second major resistance level at $17.76. The third major resistance level sits at $18.17. If the price goes on to break the first support level at $15.76, it is likely to go to the next support level at $15.35. Should the price break the second support level, the third support level stands at $14.56.
Mineralys Therapeutics Inc (NASDAQ: MLYS) Key Stats
The company with the Market Capitalisation of 1.02 billion has total of 62,785K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -177,810 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -48,950 K.
